A Randomized, Open-label, Parallel-group, Single-dose, Biocomparability Study of the Pharmacokinetics of Belatacept Drug Products Using Active Pharmaceutical Ingredient Manufactured by Process E PPQ Relative to Active Pharmaceutical Ingredient Manufactured by Process C in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 19 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Dec 2018 Planned End Date changed from 15 Sep 2018 to 15 Jan 2019.
- 24 May 2018 Planned End Date changed from 15 May 2018 to 15 Sep 2018.